Pesquisar
LENZ Therapeutics Inc
LENZAdicionar à lista de desejos
3.705USD
-0.055-1.46%
Horário de mercado 09/24, 14:27（ET）
116.15MValor de mercado
PerdaP/L TTM
Sobre o LENZ Therapeutics Inc Empresa
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
LENZ Therapeutics Inc Perfil
Código da empresaLENZ
Nome da EmpresaLENZ Therapeutics Inc
Data de listagemJun 25, 2021
CEOSchimmelpennink (Evert)
Número de funcionários42
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 25
Endereço- -
Cidade- -
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
País- -
Código postal- -
Telefone- -
Site- -
Código da empresaLENZ
Data de listagemJun 25, 2021
CEOSchimmelpennink (Evert)
Executivos da empresa LENZ Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
100.20K
+0.60%
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
100.20K
+0.60%
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
100.20K
+0.60%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
12.89K
+58.20%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
12.89K
+58.20%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
12.89K
+58.20%
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
--
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
--
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
100.20K
+0.60%
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
100.20K
+0.60%
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
100.20K
+0.60%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
12.89K
+58.20%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
12.89K
+58.20%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
12.89K
+58.20%
Perguntas frequentes
Quem são os cinco principais acionistas de LENZ Therapeutics Inc?
Os cinco principais acionistas de LENZ Therapeutics Inc são: Mr. Marc Odrich
Quantas instituições possuem ações da LENZ Therapeutics Inc (LENZ)?
Em 2026Q1, 347 instituições possuíam ações da LENZ Therapeutics Inc, com valor de mercado aproximado de 36.30M, representando 115.82% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em 853081.00.